Detailed Mechanism Funding and Narrative

Years of mechanism: 2017 2018 2019 2020

Details for Mechanism ID: 18615
Country/Region: Nigeria
Year: 2018
Main Partner: AIDS Prevention Initiative in Nigeria, LTD
Main Partner Program: Nigeria
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $25,849,145 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,488,515
Care: Orphans and Vulnerable Children (HKID) $10,712,834
Care: TB/HIV (HVTB) $199,163
Care: Pediatric Care and Support (PDCS) $492,703
Laboratory Infrastructure (HLAB) $322,575
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $1,750,532
Sexual Prevention: Other Sexual Prevention (HVOP) $1,618,479
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,045,413
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $7,925,390
Treatment: Pediatric Treatment (PDTX) $293,541
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV <10, Female, Physical and/or Emotional Violence 2019 101
GEND_GBV <10, Female, Sexual Violence (Post-Rape Care) 2019 131
GEND_GBV <10, Male, Physical and/or Emotional Violence 2019 204
GEND_GBV <10, Male, Sexual Violence (Post-Rape Care) 2019 31
GEND_GBV 10-14, Female, Physical and/or Emotional Violence 2019 128
GEND_GBV 10-14, Female, Sexual Violence (Post-Rape Care) 2019 211
GEND_GBV 10-14, Male, Physical and/or Emotional Violence 2019 74
GEND_GBV 10-14, Male, Sexual Violence (Post-Rape Care) 2019 30
GEND_GBV 15-19, Female, Physical and/or Emotional Violence 2019 269
GEND_GBV 15-19, Female, Sexual Violence (Post-Rape Care) 2019 238
GEND_GBV 15-19, Male, Physical and/or Emotional Violence 2019 44
GEND_GBV 15-19, Male, Sexual Violence (Post-Rape Care) 2019 32
GEND_GBV 20-24, Female, Physical and/or Emotional Violence 2019 456
GEND_GBV 20-24, Female, Sexual Violence (Post-Rape Care) 2019 445
GEND_GBV 20-24, Male, Physical and/or Emotional Violence 2019 190
GEND_GBV 20-24, Male, Sexual Violence (Post-Rape Care) 2019 86
GEND_GBV 25-29, Female, Physical and/or Emotional Violence 2019 1,185
GEND_GBV 25-29, Female, Sexual Violence (Post-Rape Care) 2019 338
GEND_GBV 25-29, Male, Physical and/or Emotional Violence 2019 159
GEND_GBV 25-29, Male, Sexual Violence (Post-Rape Care) 2019 38
GEND_GBV 30-34, Female, Physical and/or Emotional Violence 2019 471
GEND_GBV 30-34, Female, Sexual Violence (Post-Rape Care) 2019 134
GEND_GBV 30-34, Male, Physical and/or Emotional Violence 2019 52
GEND_GBV 30-34, Male, Sexual Violence (Post-Rape Care) 2019 14
GEND_GBV 35-39, Female, Physical and/or Emotional Violence 2019 348
GEND_GBV 35-39, Female, Sexual Violence (Post-Rape Care) 2019 94
GEND_GBV 35-39, Male, Physical and/or Emotional Violence 2019 39
GEND_GBV 35-39, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 40-49, Female, Physical and/or Emotional Violence 2019 348
GEND_GBV 40-49, Female, Sexual Violence (Post-Rape Care) 2019 94
GEND_GBV 40-49, Male, Physical and/or Emotional Violence 2019 39
GEND_GBV 40-49, Male, Sexual Violence (Post-Rape Care) 2019 9
GEND_GBV 50+, Female, Physical and/or Emotional Violence 2019 41
GEND_GBV 50+, Female, Sexual Violence (Post-Rape Care) 2019 29
GEND_GBV 50+, Male, Physical and/or Emotional Violence 2019 16
GEND_GBV 50+, Male, Sexual Violence (Post-Rape Care) 2019 1
GEND_GBV By PEP service provision (related to sexual violence services provided) 2019 1,843
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2019 4,307
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2019 2,043
GEND_GBV Number of people receiving post-GBV care 2019 6,354
HTS_SELF 2019 962
HTS_SELF 10-14, Female, Directly-Assisted 2019 3
HTS_SELF 10-14, Female, Unassisted 2019 3
HTS_SELF 10-14, Male, Directly-Assisted 2019 2
HTS_SELF 10-14, Male, Unassisted 2019 2
HTS_SELF 15-19, Female, Directly-Assisted 2019 5
HTS_SELF 15-19, Female, Unassisted 2019 5
HTS_SELF 15-19, Male, Directly-Assisted 2019 2
HTS_SELF 15-19, Male, Unassisted 2019 2
HTS_SELF 20-24, Female, Directly-Assisted 2019 56
HTS_SELF 20-24, Female, Unassisted 2019 56
HTS_SELF 20-24, Male, Directly-Assisted 2019 17
HTS_SELF 20-24, Male, Unassisted 2019 17
HTS_SELF 25-29, Female, Directly-Assisted 2019 57
HTS_SELF 25-29, Female, Unassisted 2019 57
HTS_SELF 25-29, Male, Directly-Assisted 2019 25
HTS_SELF 25-29, Male, Unassisted 2019 25
HTS_SELF 30-34, Female, Directly-Assisted 2019 56
HTS_SELF 30-34, Female, Unassisted 2019 56
HTS_SELF 30-34, Male, Directly-Assisted 2019 10
HTS_SELF 30-34, Male, Unassisted 2019 10
HTS_SELF 35-39, Female, Directly-Assisted 2019 49
HTS_SELF 35-39, Female, Unassisted 2019 49
HTS_SELF 35-39, Male, Directly-Assisted 2019 13
HTS_SELF 35-39, Male, Unassisted 2019 13
HTS_SELF 40-49, Female, Directly-Assisted 2019 62
HTS_SELF 40-49, Female, Unassisted 2019 62
HTS_SELF 40-49, Male, Directly-Assisted 2019 33
HTS_SELF 40-49, Male, Unassisted 2019 33
HTS_SELF 50+, Female, Directly-Assisted 2019 29
HTS_SELF 50+, Female, Unassisted 2019 29
HTS_SELF 50+, Male, Directly-Assisted 2019 20
HTS_SELF 50+, Male, Unassisted 2019 20
HTS_SELF Directly-Assisted 2019 481
HTS_SELF MSM, Directly-Assisted 2019 3
HTS_SELF MSM, Unassisted 2019 3
HTS_SELF PWID, Directly-Assisted 2019 11
HTS_SELF PWID, Unassisted 2019 11
HTS_SELF Unassisted 2019 481
HTS_SELF Unassisted - Other 2019 45
HTS_SELF Unassisted - Self 2019 97
HTS_SELF Unassisted - Sex Partner 2019 97
HTS_TST 1-9, Unknown Sex, Negative 2019 2,400
HTS_TST 10-14, Female, Negative 2019 800
HTS_TST 10-14, Male, Negative 2019 800
HTS_TST 15-19, Female, Negative 2019 436
HTS_TST 15-19, Male, Negative 2019 232
HTS_TST 20-24, Female, Negative 2019 326
HTS_TST 20-24, Male, Negative 2019 1,160
HTS_TST 25-29, Female, Negative 2019 435
HTS_TST 25-29, Female, Negative 2019 667
HTS_TST 25-29, Female, Negative 2019 3,587
HTS_TST 25-29, Female, Negative 2019 10,147
HTS_TST 25-29, Female, Negative 2019 26
HTS_TST 25-29, Female, Negative 2019 115,821
HTS_TST 25-29, Female, Negative 2019 126,399
HTS_TST 25-29, Female, Negative 2019 194
HTS_TST 25-29, Female, Negative 2019 325
HTS_TST 25-29, Female, Negative 2019 23,708
HTS_TST 25-29, Male, Negative 2019 1,197
HTS_TST 25-29, Male, Negative 2019 361
HTS_TST 25-29, Male, Negative 2019 2,925
HTS_TST 25-29, Male, Negative 2019 4,784
HTS_TST 25-29, Male, Negative 2019 35
HTS_TST 25-29, Male, Negative 2019 69,902
HTS_TST 25-29, Male, Negative 2019 333
HTS_TST 25-29, Male, Negative 2019 375
HTS_TST 25-29, Male, Negative 2019 11,896
HTS_TST 30-34, Female, Negative 2019 15,380
HTS_TST 30-34, Female, Negative 2019 544
HTS_TST 30-34, Female, Negative 2019 667
HTS_TST 30-34, Female, Negative 2019 2,715
HTS_TST 30-34, Female, Negative 2019 3,284
HTS_TST 30-34, Female, Negative 2019 8
HTS_TST 30-34, Female, Negative 2019 63,921
HTS_TST 30-34, Female, Negative 2019 83,973
HTS_TST 30-34, Female, Negative 2019 210
HTS_TST 30-34, Female, Negative 2019 334
HTS_TST 30-34, Male, Negative 2019 10,588
HTS_TST 30-34, Male, Negative 2019 979
HTS_TST 30-34, Male, Negative 2019 1,089
HTS_TST 30-34, Male, Negative 2019 1,822
HTS_TST 30-34, Male, Negative 2019 1,784
HTS_TST 30-34, Male, Negative 2019 11
HTS_TST 30-34, Male, Negative 2019 56,643
HTS_TST 30-34, Male, Negative 2019 161
HTS_TST 30-34, Male, Negative 2019 330
HTS_TST 35-39, Female, Negative 2019 11,094
HTS_TST 35-39, Female, Negative 2019 762
HTS_TST 35-39, Female, Negative 2019 1,112
HTS_TST 35-39, Female, Negative 2019 2,502
HTS_TST 35-39, Female, Negative 2019 1,823
HTS_TST 35-39, Female, Negative 2019 5
HTS_TST 35-39, Female, Negative 2019 50,898
HTS_TST 35-39, Female, Negative 2019 31,702
HTS_TST 35-39, Female, Negative 2019 115
HTS_TST 35-39, Female, Negative 2019 384
HTS_TST 35-39, Male, Negative 2019 7,954
HTS_TST 35-39, Male, Negative 2019 1,197
HTS_TST 35-39, Male, Negative 2019 1,329
HTS_TST 35-39, Male, Negative 2019 1,979
HTS_TST 35-39, Male, Negative 2019 742
HTS_TST 35-39, Male, Negative 2019 6
HTS_TST 35-39, Male, Negative 2019 41,283
HTS_TST 35-39, Male, Negative 2019 206
HTS_TST 35-39, Male, Negative 2019 445
HTS_TST 40-49, Female, Negative 2019 8,115
HTS_TST 40-49, Female, Negative 2019 762
HTS_TST 40-49, Female, Negative 2019 775
HTS_TST 40-49, Female, Negative 2019 2,825
HTS_TST 40-49, Female, Negative 2019 1,725
HTS_TST 40-49, Female, Negative 2019 4
HTS_TST 40-49, Female, Negative 2019 43,558
HTS_TST 40-49, Female, Negative 2019 6,865
HTS_TST 40-49, Female, Negative 2019 288
HTS_TST 40-49, Female, Negative 2019 394
HTS_TST 40-49, Male, Negative 2019 7,454
HTS_TST 40-49, Male, Negative 2019 982
HTS_TST 40-49, Male, Negative 2019 722
HTS_TST 40-49, Male, Negative 2019 2,217
HTS_TST 40-49, Male, Negative 2019 727
HTS_TST 40-49, Male, Negative 2019 6
HTS_TST 40-49, Male, Negative 2019 34,993
HTS_TST 40-49, Male, Negative 2019 209
HTS_TST 40-49, Male, Negative 2019 541
HTS_TST 50+, Female, Negative 2019 653
HTS_TST 50+, Male, Negative 2019 1,197
HTS_TST By Key Population: FSW, Negative 2019 31,082
HTS_TST By Key Population: MSM, Negative 2019 5,495
HTS_TST By Key Population: PWID, Negative 2019 6,052
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 1,595,607
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 14
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 23
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 35
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 43
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 2
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 1
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative 2019 2,267
HTS_TST Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative 2019 1,386
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative 2019 9,642
HTS_TST Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative 2019 4,182
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative 2019 1,571
HTS_TST Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative 2019 1,438
HTS_TST Service Delivery Point (Facility) ANC: 1-9, Negative 2019 3
HTS_TST Service Delivery Point (Facility) ANC: 10-14, Negative 2019 108
HTS_TST Service Delivery Point (Facility) ANC: 15-19, Negative 2019 11,564
HTS_TST Service Delivery Point (Facility) ANC: 20-24, Negative 2019 64,784
HTS_TST Service Delivery Point (Facility) ANC: 50+, Negative 2019 24
HTS_TST Service Delivery Point (Facility) Index: 1-9, Negative 2019 2,357
HTS_TST Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 634
HTS_TST Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 585
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 598
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 417
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 550
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,955
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 152
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 480
HTS_TST Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 5,372
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 1,749
HTS_TST Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 1,836
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 1,930
HTS_TST Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 1,203
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 3,637
HTS_TST Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 2,027
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 2,227
HTS_TST Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 2,275
HTS_TST Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 52,847
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 26,528
HTS_TST Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 25,463
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 43,546
HTS_TST Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 29,745
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 93,034
HTS_TST Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 60,663
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 28,667
HTS_TST Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 23,325
HTS_TST Service Delivery Point (Facility) Pediatric : <5 Negative 2019 14,871
HTS_TST Service Delivery Point (Facility) TB: <1, Negative 2019 54
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 190
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 384
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 355
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 339
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 416
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 379
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 439
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 438
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 296
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 3
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 14,838
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 14,798
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 13,811
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 15,207
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 8,259
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 27,978
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 14,928
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 9,628
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 9,050
HTS_TST Service Delivery Point (Facility)Other PITC: <1, Negative 2019 6
HTS_TST_POS 1-9, Unknown Sex, Positive 2019 1
HTS_TST_POS 10-14, Female, Positive 2019 9
HTS_TST_POS 10-14, Male, Positive 2019 9
HTS_TST_POS 20-24, Female, Positive 2019 25
HTS_TST_POS 25-29, Female, Positive 2019 416
HTS_TST_POS 25-29, Female, Positive 2019 228
HTS_TST_POS 25-29, Female, Positive 2019 1,368
HTS_TST_POS 25-29, Female, Positive 2019 18
HTS_TST_POS 25-29, Female, Positive 2019 1,877
HTS_TST_POS 25-29, Female, Positive 2019 1,887
HTS_TST_POS 25-29, Female, Positive 2019 5
HTS_TST_POS 25-29, Female, Positive 2019 21
HTS_TST_POS 25-29, Female, Positive 2019 1,825
HTS_TST_POS 25-29, Male, Positive 2019 332
HTS_TST_POS 25-29, Male, Positive 2019 270
HTS_TST_POS 25-29, Male, Positive 2019 17
HTS_TST_POS 25-29, Male, Positive 2019 963
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 25-29, Male, Positive 2019 18
HTS_TST_POS 25-29, Male, Positive 2019 347
HTS_TST_POS 30-34, Female, Positive 2019 1,122
HTS_TST_POS 30-34, Female, Positive 2019 21
HTS_TST_POS 30-34, Female, Positive 2019 249
HTS_TST_POS 30-34, Female, Positive 2019 151
HTS_TST_POS 30-34, Female, Positive 2019 320
HTS_TST_POS 30-34, Female, Positive 2019 6
HTS_TST_POS 30-34, Female, Positive 2019 1,879
HTS_TST_POS 30-34, Female, Positive 2019 262
HTS_TST_POS 30-34, Female, Positive 2019 5
HTS_TST_POS 30-34, Female, Positive 2019 27
HTS_TST_POS 30-34, Male, Positive 2019 536
HTS_TST_POS 30-34, Male, Positive 2019 13
HTS_TST_POS 30-34, Male, Positive 2019 104
HTS_TST_POS 30-34, Male, Positive 2019 88
HTS_TST_POS 30-34, Male, Positive 2019 6
HTS_TST_POS 30-34, Male, Positive 2019 484
HTS_TST_POS 30-34, Male, Positive 2019 24
HTS_TST_POS 35-39, Female, Positive 2019 988
HTS_TST_POS 35-39, Female, Positive 2019 75
HTS_TST_POS 35-39, Female, Positive 2019 416
HTS_TST_POS 35-39, Female, Positive 2019 323
HTS_TST_POS 35-39, Female, Positive 2019 180
HTS_TST_POS 35-39, Female, Positive 2019 4
HTS_TST_POS 35-39, Female, Positive 2019 1,410
HTS_TST_POS 35-39, Female, Positive 2019 260
HTS_TST_POS 35-39, Female, Positive 2019 11
HTS_TST_POS 35-39, Female, Positive 2019 30
HTS_TST_POS 35-39, Male, Positive 2019 672
HTS_TST_POS 35-39, Male, Positive 2019 34
HTS_TST_POS 35-39, Male, Positive 2019 332
HTS_TST_POS 35-39, Male, Positive 2019 176
HTS_TST_POS 35-39, Male, Positive 2019 40
HTS_TST_POS 35-39, Male, Positive 2019 8
HTS_TST_POS 35-39, Male, Positive 2019 964
HTS_TST_POS 35-39, Male, Positive 2019 7
HTS_TST_POS 35-39, Male, Positive 2019 30
HTS_TST_POS 40-49, Female, Positive 2019 1,310
HTS_TST_POS 40-49, Female, Positive 2019 40
HTS_TST_POS 40-49, Female, Positive 2019 249
HTS_TST_POS 40-49, Female, Positive 2019 157
HTS_TST_POS 40-49, Female, Positive 2019 33
HTS_TST_POS 40-49, Female, Positive 2019 7
HTS_TST_POS 40-49, Female, Positive 2019 2,350
HTS_TST_POS 40-49, Female, Positive 2019 19
HTS_TST_POS 40-49, Female, Positive 2019 43
HTS_TST_POS 40-49, Male, Positive 2019 1,261
HTS_TST_POS 40-49, Male, Positive 2019 21
HTS_TST_POS 40-49, Male, Positive 2019 227
HTS_TST_POS 40-49, Male, Positive 2019 298
HTS_TST_POS 40-49, Male, Positive 2019 31
HTS_TST_POS 40-49, Male, Positive 2019 10
HTS_TST_POS 40-49, Male, Positive 2019 1,211
HTS_TST_POS 40-49, Male, Positive 2019 20
HTS_TST_POS 40-49, Male, Positive 2019 31
HTS_TST_POS 50+, Female, Positive 2019 27
HTS_TST_POS 50+, Male, Positive 2019 13
HTS_TST_POS By Key Population: FSW, Positive 2019 1,827
HTS_TST_POS By Key Population: MSM, Positive 2019 651
HTS_TST_POS By Key Population: PWID, Positive 2019 282
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 29
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 43
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 45
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Female, Positive 2019 12
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive 2019 75
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive 2019 59
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive 2019 944
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive 2019 515
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive 2019 88
HTS_TST_POS Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) ANC: 10-14, Positive 2019 1
HTS_TST_POS Service Delivery Point (Facility) ANC: 15-19, Positive 2019 12
HTS_TST_POS Service Delivery Point (Facility) ANC: 20-24, Positive 2019 838
HTS_TST_POS Service Delivery Point (Facility) ANC: 50+, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 1-9, Positive 2019 36
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 34
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 8
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 279
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 507
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 59
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 181
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 108
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 26
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 39
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 167
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 47
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 136
HTS_TST_POS Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 92
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 528
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 271
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 285
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 479
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 144
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 2,588
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 753
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 632
HTS_TST_POS Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 407
HTS_TST_POS Service Delivery Point (Facility) Pediatric : <5 Positive 2019 143
HTS_TST_POS Service Delivery Point (Facility) TB: 1-9, Positive 2019 22
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) TB: 10-14, Male, Positive 2019 13
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 33
HTS_TST_POS Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 37
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 21
HTS_TST_POS Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Female, Positive 2019 24
HTS_TST_POS Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 15
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 370
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 354
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 370
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 340
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 169
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 1,358
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 396
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 774
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 414
KP_PREV By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 45,017
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 1,145
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 15,452
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 61,614
OVC_SERV Age/Sex: <1 2019 7,796
OVC_SERV Age/Sex: 1-9 2019 144,131
OVC_SERV Age/Sex: 10-14 Female 2019 41,194
OVC_SERV Age/Sex: 10-14 Male 2019 44,225
OVC_SERV Age/Sex: 15-17 Female 2019 16,772
OVC_SERV Age/Sex: 15-17 Male 2019 20,072
OVC_SERV By: Age/sex: 18-24 Female 2019 5,535
OVC_SERV By: Age/sex: 25+ Female 2019 49,641
OVC_SERV By: Age/sex: Male 18-24 2019 7,600
OVC_SERV By: Age/sex: Male 25+ 2019 12,824
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 349,794
OVC_SERV Program Completion: Active 2019 339,606
OVC_SERV Program Completion: Graduation 10,188 Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. 274,195 Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 349,794
OVC_SERV Sum of Age/Sex disaggregates 2019 122,263
PMTCT_ART Already on ART at beginning of current pregnancy 2019 7,235
PMTCT_ART New on ART 2019 3,451
PMTCT_ART Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 10,686
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 338,248
PMTCT_EID By infants who received a virologic test within 2 months of birth 2019 8,116
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 2,022
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 10,138
PMTCT_EID Sum of Infant Age disaggregates 2019 10,138
PMTCT_STAT 25-29, Female 2019 126,661
PMTCT_STAT 25-29, Female, Known at Entry Positive 2019 2,940
PMTCT_STAT 25-29, Female, Newly Identified Negative 2019 122,502
PMTCT_STAT 25-29, Female, Newly Identified Positive 2019 1,194
PMTCT_STAT 30-34, Female 2019 86,100
PMTCT_STAT 30-34, Female, Known at Entry Positive 2019 1,993
PMTCT_STAT 30-34, Female, Newly Identified Negative 2019 83,259
PMTCT_STAT 30-34, Female, Newly Identified Positive 2019 810
PMTCT_STAT 35-39, Female 2019 34,451
PMTCT_STAT 35-39, Female, Known at Entry Positive 2019 767
PMTCT_STAT 35-39, Female, Newly Identified Negative 2019 33,314
PMTCT_STAT 35-39, Female, Newly Identified Positive 2019 251
PMTCT_STAT 40-49, Female 2019 7,284
PMTCT_STAT 40-49, Female, Known at Entry Positive 2019 142
PMTCT_STAT 40-49, Female, Newly Identified Negative 2019 7,024
PMTCT_STAT 40-49, Female, Newly Identified Positive 2019 32
PMTCT_STAT By Age (Numerator): 10-14 2019 633
PMTCT_STAT By Age (Numerator): 15-19 2019 13,511
PMTCT_STAT By Age (Numerator): 20-24 2019 68,600
PMTCT_STAT By Age (Numerator): 50+ 2019 1,699
PMTCT_STAT By Number of known positives: 15-19 2019 317
PMTCT_STAT By Number of known positives: 20-24 2019 1,654
PMTCT_STAT By Number of known positives: 50+ 2019 14
PMTCT_STAT By Number of new negative: 10-14 2019 597
PMTCT_STAT By Number of new negative: 15-19 2019 13,009
PMTCT_STAT By Number of new negative: 20-24 2019 66,256
PMTCT_STAT By Number of new negative: 50+ 2019 1,641
PMTCT_STAT By Number of new positives: 15-19 2019 130
PMTCT_STAT By Number of new positives: 20-24 2019 661
PMTCT_STAT By Number of new positives: 50+ 2019 13
PMTCT_STAT Number of new ANC and L&D clients 2019 356,785
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 338,248
PMTCT_STAT_den 25-29, Female 2019 133,341
PMTCT_STAT_den 30-34, Female 2019 90,625
PMTCT_STAT_den 35-39, Female 2019 36,276
PMTCT_STAT_den 40-49, Female 2019 7,669
PMTCT_STAT_den By Age (Denominator): <15-19 2019 14,210
PMTCT_STAT_den By Age (Denominator): 10-14 2019 675
PMTCT_STAT_den By Age (Denominator): 20-24 2019 72,206
PMTCT_STAT_den By Age (Denominator): 50+ 2019 1,783
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 38
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1,098
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 24
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 1,217
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 2,357
TB_PREV By Age/Sex (Numerator): <15, Female 2019 2,636
TB_PREV By Age/Sex (Numerator): <15, Male 2019 2,372
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 107,802
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 49,833
TB_PREV IPT, Life-long ART, Already, Positive 2019 154,489
TB_PREV IPT, Life-long ART, New, Positive 2019 8,140
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 162,615
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 180,682
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 1,820
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 2,452
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 124,908
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 51,532
TB_PREV_den IPT, Life-long ART, Already, Positive 2019 171,660
TB_PREV_den IPT, Life-long ART, New, Positive 2019 9,031
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 227
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 3,352
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 265
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 4,522
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 8,363
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 8,363
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 227
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 3,352
TB_STAT_den Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 265
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 4,522
TX_CURR 25-29, Female, Positive 2019 24,479
TX_CURR 25-29, Male, Positive 2019 7,296
TX_CURR 30-34, Female, Positive 2019 37,976
TX_CURR 30-34, Male, Positive 2019 7,823
TX_CURR 35-39, Female, Positive 2019 39,447
TX_CURR 35-39, Male, Positive 2019 11,055
TX_CURR 40-49, Female, Positive 2019 49,564
TX_CURR 40-49, Male, Positive 2019 23,535
TX_CURR Age/Sex: <1 2019 155
TX_CURR Age/Sex: <1-9 2019 10,914
TX_CURR Age/Sex: 10-14 Female 2019 2,934
TX_CURR Age/Sex: 10-14 Male 2019 3,008
TX_CURR Age/Sex: 15-19 Female 2019 3,096
TX_CURR Age/Sex: 15-19 Male 2019 1,547
TX_CURR Age/Sex: 20-24 Female 2019 12,494
TX_CURR Age/Sex: 20-24 Male 2019 1,957
TX_CURR Age/Sex: 50+ Female 2019 29,554
TX_CURR Age/Sex: 50+ Male 2019 18,581
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 285,265
TX_CURR Sum of age/sex disaggregates 2019 4,643
TX_NEW 25-29, Female, Positive 2019 4,773
TX_NEW 25-29, Male, Positive 2019 1,966
TX_NEW 30-34, Female, Positive 2019 3,042
TX_NEW 30-34, Male, Positive 2019 1,235
TX_NEW 35-39, Female, Positive 2019 3,791
TX_NEW 35-39, Male, Positive 2019 1,547
TX_NEW 40-49, Female, Positive 2019 5,908
TX_NEW 40-49, Male, Positive 2019 2,427
TX_NEW Breastfeeding status 2019 174
TX_NEW By Age/Sex: <1 2019 324
TX_NEW By Age/Sex: 1-9 2019 1,624
TX_NEW By Age/Sex: 10-14 Female 2019 425
TX_NEW By Age/Sex: 10-14 Male 2019 326
TX_NEW By Age/Sex: 15-19 Female 2019 778
TX_NEW By Age/Sex: 15-19 Male 2019 197
TX_NEW By Age/Sex: 20-24 Female 2019 5,500
TX_NEW By Age/Sex: 20-24 Male 2019 2,110
TX_NEW By Age/Sex: 50+ Female 2019 2,045
TX_NEW By Age/Sex: 50+ Male 2019 1,551
TX_NEW By Key populations: People who inject drugs (PWID) 2019 36
TX_NEW FSW 2019 897
TX_NEW MSM 2019 264
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 39,504
TX_NEW Pregnancy status 2019 1,507
TX_NEW Sum of Age/Sex disaggregates 2019 12,932
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 288,357
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 5,647
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 22
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 7,300
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted 2019 32
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 188,547
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted 2019 462
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 86,209
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted 2019 42
TX_PVLS_den Denominator: Indication: Routine 2019 287,704
TX_PVLS_den Denominator: Indication: Targeted 2019 558
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,263
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,306
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 25,725
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 9,617
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 37,925
TX_RET Numerator by Status: Breastfeeding 2019 177
TX_RET Numerator by Status: Pregnant 2019 1,514
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 42,139
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,407
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,445
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 28,305
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 10,963
TX_RET_den Denominator by Status: Breastfeeding 2019 195
TX_RET_den Denominator by Status: Pregnant 2019 1,678
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 291,433
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 9,577
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 8,220
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 198,757
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 74,902
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 232,745
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 232,745
TX_TB_den Life-long ART, Already, TB Screen - Negative, Positive 2019 140,942
TX_TB_den Life-long ART, Already, TB Screen - Positive, Positive 2019 38,835
TX_TB_den Life-long ART, New, TB Screen - Negative, Positive 2019 93,964
TX_TB_den Life-long ART, New, TB Screen - Positive, Positive 2019 17,734
Cross Cutting Budget Categories and Known Amounts Total: $1,715,991
Gender: Gender Based Violence (GBV) $959,693
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research
Gender: Gender Equality $206,000
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Capacity building
Implementation
Monitoring and Evaluation
Operation Research
Food and Nutrition: Commodities $72,896
Water $80,055
Economic Strengthening $340,179
Food and Nutrition: Policy, Tools, and Service Delivery $42,588
Education $14,580